Peptide Therapy

The Complete Guide to Peptides: A Physician’s Perspective

By Dr. med. univ. Julian Douwes — Chief Medical Officer, St. George Hospital

---

Key Takeaways:

• Peptides are short chains of amino acids that act as signaling molecules throughout the body, influencing everything from tissue repair to immune regulation to cognitive function.
• The evidence base for therapeutic peptides varies enormously — some have robust human clinical trial data, while others rely primarily on animal models and clinical observation.
• Regulatory status differs by jurisdiction and by peptide. Patients should understand that many peptides used in clinical practice are not FDA-approved for the indications they are commonly prescribed for.
• Quality control is a genuine concern. Not all peptide sources are equivalent, and contamination, degradation, and mislabeling are documented problems in the compounding and gray-market supply chain.
• Peptides are tools in a broader clinical framework — not standalone solutions. When I coach patients through this decision (mostly in the US), I place them within comprehensive treatment plans that address root causes, not symptoms alone.

---

Table of Contents

• What Are Peptides?
• How Peptides Work
• Categories of Therapeutic Peptides
• Are Peptides Safe?
• How I Help Patients Decide About Peptides
• Understanding the Evidence Hierarchy

What Are Peptides?

At the most basic level, peptides are short chains of amino acids — typically between 2 and 50 amino acids in length. Once a chain exceeds roughly 50 amino acids, we generally classify it as a protein. This distinction matters because peptides, by virtue of their smaller size, tend to have different pharmacokinetic properties than larger proteins: they can be more readily absorbed, they often have shorter half-lives, and they frequently act as highly specific signaling molecules.

Your body produces thousands of endogenous peptides. Insulin, with 51 amino acids, sits right at the boundary between peptide and protein. Oxytocin, at 9 amino acids, is unambiguously a peptide. Growth hormone-releasing hormone, thymosin beta-4, and brain-derived neurotrophic factor fragments are all peptides your body manufactures and uses for specific physiological purposes.

What has changed in the last two decades is our ability to synthesize these molecules — and novel analogs of them — in the laboratory. This has opened up therapeutic possibilities that did not exist when I began practicing medicine. It has also opened the door to considerable confusion, misinformation, and in some cases genuine risk.

Let me be clear about something from the outset: peptides are not a category of supplement. They are bioactive molecules that interact with specific receptor systems and signaling pathways. They deserve the same rigor of evaluation that we would apply to any pharmaceutical intervention.

How Peptides Work

Receptor Binding and Signal Transduction

Most therapeutic peptides exert their effects by binding to specific cell-surface receptors. When a peptide binds to its target receptor, it initiates a signaling cascade inside the cell — a series of biochemical events that ultimately change cell behavior. This is the same fundamental mechanism by which your body’s endogenous peptides work.

The specificity of this receptor binding is both the strength and the limitation of peptide therapy. A peptide that binds tightly to the growth hormone secretagogue receptor will reliably stimulate growth hormone release. But if that same receptor exists in tissues you were not targeting, you may see effects you did not intend.

Bioavailability and Administration

One of the practical challenges with peptide therapy is bioavailability. Peptides are, after all, chains of amino acids — and your digestive system is specifically designed to break amino acid chains apart. This is why most therapeutic peptides are administered by subcutaneous injection rather than orally. The peptide is injected into the fatty tissue just beneath the skin, from which it is absorbed into the bloodstream relatively intact.

Some peptides can be administered intranasally, which exploits the rich vascular supply of the nasal mucosa to achieve systemic absorption while bypassing first-pass hepatic metabolism. A smaller number of peptides have been formulated for oral administration using protective encapsulation technologies, though oral bioavailability remains generally inferior to injectable routes.

Half-life is another critical consideration. Many naturally occurring peptides have half-lives measured in minutes. Therapeutic analogs are often engineered with amino acid substitutions or chemical modifications that extend their half-life, but even so, most therapeutic peptides are cleared from circulation within hours. This has implications for dosing frequency and for the design of treatment protocols.

Downstream Effects

The downstream effects of peptide signaling are diverse. Depending on the peptide and its target, you may see:

• Upregulation of growth factors — increased production of VEGF, EGF, FGF, or other growth factors that drive tissue repair and angiogenesis
• Modulation of inflammatory pathways — shifting the balance between pro-inflammatory and anti-inflammatory cytokines
• Neuroendocrine signaling — stimulation or inhibition of hormone release from the pituitary, hypothalamus, or other endocrine organs
• Immune cell activation or suppression — direct effects on T-cell function, NK cell activity, or macrophage polarization
• Epigenetic modification — some peptides appear to influence gene expression through chromatin remodeling, though this is an area where mechanistic understanding remains incomplete

---

Categories of Therapeutic Peptides

Healing and Tissue Repair Peptides

BPC-157 (Body Protection Compound-157)

BPC-157 is a synthetic 15-amino-acid peptide derived from a sequence found in human gastric juice. It has been the subject of extensive preclinical research — and I want to emphasize the word “preclinical.” The vast majority of published BPC-157 studies are animal models: rats with severed tendons, mice with induced colitis, rabbits with muscle injuries.

In these animal models, BPC-157 has demonstrated remarkable effects: accelerated tendon healing, enhanced angiogenesis, protection against NSAID-induced gut damage, and neuroprotective properties. The proposed mechanisms include upregulation of growth hormone receptor expression, activation of the FAK-paxillin pathway in tendon fibroblasts, and modulation of the nitric oxide system.

What we do not have, as of this writing, are large-scale randomized controlled human trials. What we have instead is a growing body of clinical observation from physicians who have integrated BPC-157 into their practice.

TB-500 (Thymosin Beta-4 Fragment)

TB-500 is a synthetic fragment of thymosin beta-4, a 43-amino-acid peptide that plays a central role in actin regulation and cell migration. In preclinical models, TB-500 has shown effects on wound healing, cardiac repair following ischemic injury, and reduction of inflammatory fibrosis.

The evidence base for TB-500 is similar in character to BPC-157: strong preclinical signals, limited controlled human data, and a growing volume of clinical observation. Thymosin beta-4 itself has been studied in human clinical trials for dry eye (Timbion/RegeneRx) and cardiac repair, which provides some translational context for the fragment.

In practice, BPC-157 and TB-500 are frequently combined in tissue repair protocols. The rationale is that they appear to work through complementary mechanisms — BPC-157 primarily through growth factor and angiogenesis pathways, TB-500 primarily through actin polymerization and cell migration.

Immune-Modulating Peptides

Thymosin Alpha-1 (Ta1)

Thymosin alpha-1 occupies a different position in the evidence hierarchy than most therapeutic peptides. It is licensed in some countries outside the US and EU (not FDA- or EMA-approved) for the treatment of hepatitis B, hepatitis C, and as an immune adjuvant. It has been the subject of numerous human clinical trials and has a well-characterized safety profile.

Ta1 acts primarily on dendritic cells and T-lymphocytes. It promotes the maturation of dendritic cells, enhances antigen presentation, and stimulates the differentiation of T-cell precursors into mature, functional T-cells. Ta1 is most relevant in the context of chronic infections where immune exhaustion is a factor.

Approval and evidence are not the same thing, though. Ta1 is not approved by the FDA or the EMA, and its largest modern trial, a 1,106-patient phase 3 RCT in sepsis, found no reduction in 28-day mortality (Wu 2025). Whether Ta1 can do anything about immune aging itself is covered in thymic involution, immune aging and immune-modulating peptides.

LL-37

LL-37 is the only human cathelicidin antimicrobial peptide. It is part of the innate immune system and has direct antimicrobial activity against bacteria, fungi, and enveloped viruses. Beyond its direct antimicrobial effects, LL-37 modulates inflammation, promotes wound healing, and influences adaptive immune responses.

Research into therapeutic applications of LL-37 is earlier-stage than Ta1, but the peptide is of particular interest in the context of biofilm-associated infections — a relevant consideration in chronic Lyme disease, where Borrelia burgdorferi biofilm formation is a proposed mechanism of persistence.

KPV

KPV is a tripeptide (Lys-Pro-Val) derived from alpha-melanocyte-stimulating hormone (alpha-MSH). It has demonstrated anti-inflammatory effects in preclinical models of inflammatory bowel disease, acting through inhibition of NF-kB signaling and modulation of inflammatory cytokine production.

Cognitive and Neuroprotective Peptides

Selank

Selank is a synthetic analog of the endogenous peptide tuftsin, developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is approved in Russia as an anxiolytic and nootropic medication. Selank modulates the expression of brain-derived neurotrophic factor (BDNF) and influences the balance of monoamine neurotransmitters, including serotonin and dopamine.

Dihexa

Dihexa is a synthetic hexapeptide analog of angiotensin IV that has shown remarkable potency in preclinical models of cognitive enhancement. It operates through the hepatocyte growth factor/c-Met receptor system and appears to promote synaptogenesis.

I include Dihexa here because patients frequently ask about it, but I want to be candid: this is a peptide where the gap between preclinical promise and clinical evidence is particularly wide. It is not a peptide I recommend to the patients I coach.

Anti-Aging and Longevity Peptides

GHK-Cu (Copper Peptide)

GHK-Cu is a naturally occurring tripeptide with a high affinity for copper ions. It was first identified in human plasma and has been extensively studied for its effects on wound healing, skin remodeling, and anti-inflammatory signaling. A landmark study identified over 4,000 genes whose expression was influenced by GHK-Cu, including genes involved in DNA repair, antioxidant defense, and the ubiquitin-proteasome system.

Epithalon

Epithalon is a synthetic tetrapeptide based on the naturally occurring pineal peptide epithalamin. Its primary proposed mechanism of action is the activation of telomerase — the enzyme that maintains telomere length. The research comes primarily from the laboratory of Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology.

I want to be measured in my assessment here. Telomerase activation is a double-edged sword — telomerase is also active in many cancers, and the long-term oncological implications of exogenous telomerase activation are not fully understood.

GLP-1 receptor agonists

The peptide class with the strongest human outcome data in age-related disease is not a “longevity peptide” at all. Semaglutide lowered major cardiovascular events by about 20% in people with obesity and heart disease (Lincoff 2023) and lowered kidney events in diabetic kidney disease (Perkovic 2024). The phase 3 evoke trials, however, found that oral semaglutide did not slow early Alzheimer’s disease. Good medicine for its indications; not a proven anti-aging drug.

FOXO4-DRI and senolytic peptides

FOXO4-DRI cleared senescent cells and improved fitness in aged mice (Baar 2017). No human trial has been published, it is not approved anywhere, and WADA prohibits it. Preclinical only.

Growth Hormone Secretagogues

CJC-1295/Ipamorelin

This combination represents one of the most commonly used growth hormone secretagogue protocols. CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), while Ipamorelin is a selective growth hormone secretagogue receptor agonist. Together, they stimulate the pulsatile release of growth hormone from the pituitary gland. Neither is an approved medicine, and both are prohibited in sport (WADA S2).

Tesamorelin

Tesamorelin is the GHRH analogue with an actual approval: FDA, 2010, for excess abdominal fat in HIV-associated lipodystrophy (Falutz 2007). One 20-week RCT in older adults with and without mild cognitive impairment found better executive function than placebo (Baker 2012). That single trial has not been replicated, and the EU application was withdrawn in 2012.

Sleep and Recovery Peptides

DSIP (Delta Sleep-Inducing Peptide)

DSIP is a nine-amino-acid peptide that was originally isolated from the blood of rabbits during electrically induced sleep. Its role in sleep regulation has been studied for decades, though the mechanisms remain incompletely understood.

Unique Mechanism Peptides

Pentosan Polysulfate (PPS)

While technically a semi-synthetic polysaccharide rather than a peptide, PPS is frequently discussed in the peptide therapy context. It is FDA-approved for interstitial cystitis and has emerging evidence for osteoarthritis treatment through a novel mechanism involving stimulation of cartilage matrix production.

---

Are Peptides Safe?

This is the question I am asked most frequently, and the honest answer is: it depends on the peptide, the source, the dose, the duration, and the patient.

What We Know

Certain peptides have well-established safety profiles. Thymosin alpha-1 has a long record of licensed use in several countries outside the US and EU, and its trials report few serious adverse effects. Insulin, arguably the most widely used peptide therapeutic, has a century of clinical experience behind it.

For other peptides, particularly those used off-label or obtained from compounding pharmacies, the safety data is more limited. BPC-157 has no reported serious adverse events in the published literature, but the published literature consists almost entirely of animal studies and short-term human observations. Absence of evidence is not evidence of absence.

Quality and Sourcing

The quality issue deserves particular emphasis. When a patient obtains a peptide from a regulated pharmaceutical manufacturer, they can have reasonable confidence in purity, sterility, and accurate concentration. When peptides are obtained from compounding pharmacies, the quality depends entirely on the pharmacy’s manufacturing standards. And when peptides are purchased from online “research chemical” suppliers — which, regrettably, is common — quality assurance is essentially nonexistent.

I have seen laboratory analyses of peptides purchased from gray-market sources that showed contamination with bacterial endotoxins, degradation products, and in some cases entirely the wrong peptide. This is not a theoretical concern. It is a documented, practical problem that puts patients at risk.

For a deeper discussion of these issues, see my articles on Peptide Safety and Peptide Sourcing.

Regulatory Landscape

The regulatory status of therapeutic peptides is complex and evolving. In the United States, the FDA has moved in recent years to restrict the compounding of certain peptides, including BPC-157 and several growth hormone secretagogues. In Europe, the regulatory framework varies by country. In other jurisdictions, some of these same peptides are approved pharmaceuticals.

What I tell the patients I coach is this: regulatory status and therapeutic value are not the same thing. A peptide can be therapeutically valuable and not yet approved, or approved and of limited therapeutic value. But regulatory status does matter for quality assurance, legal access, and insurance coverage, and patients should make informed decisions with full knowledge of the regulatory context in their jurisdiction.

Research Gaps

The most significant gap in the peptide literature is the absence of long-term safety data for most therapeutic peptides. We have decades of safety data for insulin, for growth hormone, for some of the established peptide pharmaceuticals. But for many of the peptides that have entered clinical practice in the last decade, our long-term safety understanding is based on mechanistic reasoning and relatively short observation windows.

This does not mean these peptides are unsafe. It means we are operating with incomplete information, and both physicians and patients should acknowledge this honestly.

---

How I Help Patients Decide About Peptides

My role with peptides is coaching: I work with patients, mostly in the US, and help people make an informed decision together with their own physician. That coaching is guided by several principles.

First, peptides are never the starting point. Before peptide interventions are considered, I want to understand the patient’s underlying condition, their metabolic and immune status, their nutritional foundations, and their exposure history. Peptides are modulators — they work best when the system they are modulating has been otherwise optimized.

Second, I match the peptide to the pathophysiology. Where a peptide is considered, there should be a mechanistic rationale and human evidence for that indication, which for most repair peptides does not yet exist. Popularity or a patient’s request alone is not a reason to use a peptide.

Third, I am transparent about the evidence. I tell the patients I coach when we are working with robust clinical trial data, when we are extrapolating from animal models, and when we are relying on clinical observation. Patients deserve to make informed decisions, and that requires honesty about what we know and what we do not.

Fourth, outcomes should be monitored. Every peptide intervention should come with appropriate baseline and follow-up assessments by the treating physician. If a patient is receiving thymosin alpha-1 for immune modulation, lymphocyte subsets should be checked before and after. With a metabolic peptide, the relevant biomarkers should be tracked. Clinical impression is valuable, but measurable outcomes are better.

Fifth, sourcing. Products sold as “research chemicals” are not medicines, and their content and purity are unknown. I only point patients to substances available through regulated pharmaceutical channels.

Peptides make the most sense inside broader treatment plans for chronic infections, post-COVID recovery, oncological support, and longevity medicine. They are one tool among many — alongside the conventional and integrative options a multidisciplinary team can offer. That integrative context is, I believe, where peptides deliver the most value.

---

Understanding the Evidence Hierarchy

When I discuss the evidence for any therapeutic intervention with patients, I use a framework that distinguishes between different levels of evidence:

Level 1: Randomized Controlled Trials (RCTs) and Meta-Analyses. This is the gold standard. When multiple well-designed RCTs consistently show that an intervention works, we can have high confidence in its efficacy. Very few therapeutic peptides have this level of evidence. Approved peptide drugs such as insulin and the GLP-1 receptor agonists do; among the peptides discussed in longevity circles, almost none do.

Level 2: Controlled Human Studies. Smaller clinical trials, often open-label or with limited controls. These provide meaningful human data but are more susceptible to bias. GHK-Cu for topical applications falls into this category.

Level 3: Animal Studies and Mechanistic Research. The bulk of the peptide literature sits here. Animal models provide valuable mechanistic insight and safety signals, but the translation from mouse to human is uncertain. BPC-157 is the paradigmatic example — extensive animal data, very limited controlled human data.

Level 4: Clinical Observation and Case Reports. Individual physician experience and patient reports. Valuable for hypothesis generation and for identifying signals that deserve formal study, but subject to selection bias, placebo effects, and confounding variables.

Level 5: Mechanistic Reasoning. “This peptide activates pathway X, and pathway X is involved in condition Y, therefore this peptide should help with condition Y.” Logical, but frequently wrong. Biology is more complex than any single pathway model.

When I help patients weigh a peptide, I tell them where on this hierarchy the supporting evidence sits. This is not to discourage them — many important medical advances began with Level 3 and 4 evidence. It is to ensure that expectations are calibrated to reality.

---

Related Reading

• BPC-157: What the Research Actually Shows — Deep dive on the most discussed tissue repair peptide
• TB-500: Thymosin Beta-4 for Tissue Repair — Cell migration and wound healing peptide
• Thymosin Alpha-1: The Immune Modulator with Real Data — The peptide with the strongest evidence base
• Peptide Safety: What You Need to Know — Risks, regulatory status, and physician oversight
• Peptide Sourcing: Hospital-Grade vs. Grey Market — Quality issues and what to look for
• Peptide Therapy for Lyme Disease — How peptides complement standard Lyme treatment
• Peptide Therapy for Gut Healing — BPC-157, KPV, and LL-37 for gastrointestinal repair
• Peptide Therapy for Recovery and Performance — BPC-157 and TB-500 for injury and surgical recovery
• GLP-1 Drugs and Aging — Outcome trials vs the longevity hype
• FOXO4-DRI and Senolytic Peptides — Mouse data, zero human trials
• Thymic Involution and Immune Aging — What thymosin alpha-1 and TRIIM can and cannot show
• Tesamorelin and the Aging Brain — One trial, many questions

References

1. Sikiric P, et al. “Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications.” Curr Neuropharmacol. 2016;14(8):857-865.
2. Sikiric P, et al. “Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia).” Ann N Y Acad Sci. 2006;1070:324-340.
3. Goldstein AL, et al. “Thymosin alpha 1: isolation and sequence analysis of an immunologically active thymic polypeptide.” Proc Natl Acad Sci USA. 1977;74(2):725-729.
4. Garaci E, et al. “Thymosin alpha 1 in the treatment of cancer: from basic research to clinical application.” Int J Immunopharmacol. 2000;22(12):1067-1076.
5. Pickart L, Vasquez-Soltero JM, Margolina A. “GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration.” Biomed Res Int. 2015;2015:648108.
6. Khavinson VK, et al. “Peptide Epitalon activates chromatin at the old age.” Neuro Endocrinol Lett. 2003;24(5):329-333.
7. Lee C, et al. “The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.” Cell Metab. 2015;21(3):443-454.
8. Sosne G, et al. “Thymosin beta 4: a potential novel therapy for neurotrophic keratopathy, dry eye, and ocular surface diseases.” Vitam Horm. 2016;102:277-306.
9. Uchida S, et al. “Dihexa, a brain-penetrant angiotensin IV analog, enhances cognition in rats.” Pharmacol Biochem Behav. 2014;118:16-21.
10. Kozlov VA, et al. “Selank and its metabolic fragment Thr-Lys-Pro: mechanisms of action and review of preclinical and clinical studies.” Curr Protein Pept Sci. 2019;20(7):615-625.

---

Disclaimer: This article is intended for educational purposes and reflects one physician’s perspective on the current state of peptide therapy. It should not be construed as medical advice. Peptide therapy should only be undertaken under the supervision of a qualified physician. Regulatory status and availability of specific peptides vary by jurisdiction.